Cyclopharm (ASX:CYC) has capped off 2025 with record operating revenue, marking a pivotal year in the company’s transformation as the United States rapidly becomes its most important market. …
Cyclopharm delivers record revenue as US emerges as growth engine
February 2, 2026 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Cyclopharm delivers record revenue as US emerges as growth engine
February 2, 2026 - - Australian Biotech -
Sandoz adds to vision care options with the listing of biosimilar aflibercept
February 2, 2026 - -
PYC’s capital raise marks one of the largest biotech fundraisings in Australian market history
February 2, 2026 - - Australian Biotech -
Genetic Signatures appoints seasoned life sciences executive as CEO
February 2, 2026 - - Australian Biotech -
EMA decision clears regulatory path for Argenica’s lead stroke drug in Europe
February 2, 2026 - - Australian Biotech -
Recce Pharmaceuticals deepens US partnership to advance burn wound treatment
February 2, 2026 - - Australian Biotech -
Another potential turning point for immunotherapy access in Australia
February 1, 2026 - - Latest News